Rocatinlimab achieved a 32.8% EASI-75 response at week 24, but fell short of market leader Dupixent’s results. Uplizna improved MG-ADL and QMG scores significantly, offering potential as a ...
Rocatinlimab could achieve $4 billion in sales by 2035, despite mixed trial results, due to a favorable safety profile and convenience. Uplizna shows significant sales potential in generalized ...